3 Great Healthcare Stocks to Buy Now

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Get Merck & Co., Inc. alerts:

g class="alignleft" src="https://www.marketbeat.com/logos/articles/small_Depositphotos_5057916_S.jpg" alt="3 Great Healthcare Stocks to Buy Now" width="660" height="330" />

Healthcare Stocks Are Appealing in Any Market Environment

It’s fair to say that the healthcare sector is one of the most intriguing areas of the market for investors to explore. After all, a global pandemic has reminded the world of just how important quality medical care is. Healthcare spending in the U.S. accounted for over 19.7% of the country’s GDP in 2020, and that number is expected to get even larger over the next decade. Naturally, there will be plenty of companies that are able to take advantage of this growth, which is why the sector is worth a look for new investment opportunities even during a period of elevated market volatility.

Investors might be in store for some very appealing buying opportunities in 2022 if January is any indication of how the year might unfold in markets, and focusing on a sector like healthcare makes a lot of sense given how the industry will always see heavy spending regardless of economic conditions. That’s why we’ve put together the following list of 3 great healthcare stocks to buy now. Let's take a closer look at these fantastic companies below.

McKesson Corp (NYSE: MCK)

If you’re looking for one of the strongest stocks in the market, look no further than McKesson Corp. The stock is roughly flat year-to-date while major indices are getting pummeled, which tells investors that it’s showing a lot of relative strength. McKesson is the largest distributor of pharmaceuticals in the U.S. and also distributes medical-surgical supplies, an intriguing business model that is poised to deliver double-digit adjusted EPS growth going forward. The company should see its pharmaceutical sales increase in 2022 thanks to higher prescription volumes as visits to primary care doctors get back to normal after the pandemic.

McKesson's management raised its forward guidance for FY22 last quarter and also delivered total revenues of $66.6 billion in Q2, up 9% year-over-year, which are both signs of a healthy business. The bottom line here is that McKesson is a dominant force in the pharmaceutical industry with plenty of upside for long-term shareholders to consider, and the fact that the stock price is barely being impacted by the current market weakness speaks volumes about the quality of this company.

HCA Healthcare Inc (NYSE: HCA)

HCA Healthcare is an underrated healthcare company that has come out of the pandemic a more efficient business, which is why it should be on your shopping list at this time. As one of the largest hospital companies in the United States, HCA has the leading market share in some of the largest areas in the country including Texas and Florida. The company has focused on improving its cost structure over the last few years, which is a move that should pay off over the long term in the form of improved margins. There’s also a good chance HCA will benefit from a rebound in elective procedures going forward, which is another strong reason to consider adding shares.

The company delivered its fourth straight quarterly earnings beat back in October, which saw HCA deliver EPS of $4.57, up from $1.92 in 2020, on revenue of $15.3 billion, up 15% year-over-year. The company will announce its Q4 results on January 27th and could be gearing up for another strong report, so keep an eye on the market's reaction to those numbers towards the end of the month. With the stock heading closer to testing the 200-day moving average, investors might want to consider the recent weakness in this leading health care services provider as an intriguing opportunity to scoop up shares.

Merck & Co (NYSE: MRK)

If you’re interested in exposure to a leading biopharmaceutical company that pays a very appealing dividend, Merck & Co is a solid option to consider. The company’s major drugs include treatments in oncology and diabetes, and Merck also produces vaccines and animal health medications, rounding out a diverse portfolio of products. The company’s COVID-19 antiviral pill Molnupiravir has been granted emergency use authorization for the treatment of mild-to-moderate coronavirus disease, and it will be interesting to see if it becomes a big winner for the company.

Merck has also announced an agreement to acquire Acceleron, which is a biotech firm that develops therapies for serious and rare diseases. This move improves Merck’s pipeline of new drugs and its cardiovascular disease treatment portfolio and should certainly be viewed as a positive from long-term investors. It’s also worth noting that the company has been delivering strong earnings recently, including Q3 adjusted EPS of $1.75, up 28% year-over-year. Finally, the fact that Merck stock offers investors a 3.42% dividend yield makes it a top pick in the sector.

→ Strange new buyer driving up gold (From Stansberry Research) (Ad)

Should you invest $1,000 in Merck & Co., Inc. right now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Companies Mentioned in This Article

Company	MarketRank™	Current Price	Price Change	Dividend Yield	P/E Ratio	Consensus Rating	Consensus Price Target
Merck & Co., Inc. (MRK)	4.7583 of 5 stars	$125.66	+0.3%	2.45%	897.57	Moderate Buy	$131.25
HCA Healthcare (HCA)	4.8174 of 5 stars	$304.92	+2.7%	0.87%	16.07	Moderate Buy	$314.05
McKesson (MCK)	4.7582 of 5 stars	$524.47	+1.1%	0.47%	23.76	Moderate Buy	$533.50